Questions and answers
6 December 2022
What is the current evidence on lung cancer screening?
How can risk prediction and biomarkers contribute to make lung cancer screening more effective and efficient?
What role could artificial intelligence play in lung cancer screening?
Dr Rosa GiulianiConsultant in Medical Oncology, Clatterbridge Cancer Centre, United Kingdom
Director of Public Policy, European Society for Medical Oncology (ESMO)
LUNG CANCER SCREENING: WHERE DO WE STAND?
Professor Joachim AertsHead, Department of Pulmonary Medicine
Erasmus University Medical Center, Netherlands
There is a lot of debate about the efficacy of lung cancer screening. This presentation will discuss the latest state of affairs of the published data on lung cancer screening
THE FUTURE OF LUNG CANCER SCREENING: RISK PREDICTION, BIOMARKERS, AND ARTIFICIAL INTELLIGENCE
Dr Hilary RobbinsScientist, Genomic Epidemiology Branch
International Agency for Research on Cancer, Lyon, France
Lung cancer screening programmes can be made more effective and efficient by using information about individual risk to tailor aspects of eligibility, screening frequency, and nodule follow-up. This presentation will discuss research developments in predicting lung cancer occurrence using statistical models, blood-based biomarkers, and artificial intelligence with low-dose computed tomography (CT) images.
To access the content: 1) login/register to the platform; 2) click on the “Enrol” button. The page will refresh and you will be able to click on the cards below.
Organized with the support of and in collaboration with the European Society for Medical Oncology (ESMO).